Canopy Growth (CGC) Receives a Hold from MKM Partners
In a report released today, William Kirk from MKM Partners maintained a Hold rating on Canopy Growth (CGC), with a price target of C$21.00. The company’s shares closed last Monday at $22.13.
According to TipRanks.com, Kirk is ranked #4760 out of 5917 analysts.
Canopy Growth has an analyst consensus of Moderate Buy, with a price target consensus of $24.07, which is a 3.9% upside from current levels. In a report issued on February 14, PI Financial also downgraded the stock to Hold with a C$30.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $52.74 and a one-year low of $13.81. Currently, Canopy Growth has an average volume of 8.9M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite.
Read More on CGC: